Interleukin-1 beta production pathway (IL-1β pathway)

The Interleukin-1 beta (IL-1β) production pathway is a critical innate immune signaling cascade responsible for the generation and release of the potent pro-inflammatory cytokine IL-1β (Nature Reviews Immunology, 2017). This pathway typically operates via a two-signal mechanism: a priming signal that induces the transcription of the inactive pro-IL-1β precursor and an activation signal that triggers the assembly of the NLRP3 inflammasome complex (StatPearls, 2023). Once assembled, the inflammasome activates Caspase-1, which cleaves pro-IL-1β into its active form, leading to its secretion and the induction of inflammatory responses, including fever and recruitment of immune cells (Cell, 2018). Dysregulation of this pathway is central to the pathogenesis of various autoinflammatory syndromes, such as Cryopyrin-Associated Periodic Syndromes (CAPS), and contributes to chronic inflammatory conditions like gout, rheumatoid arthritis, and atherosclerosis (Journal of Clinical Investigation, 2015). Therapeutic strategies targeting this pathway include the use of monoclonal antibodies to neutralize IL-1β, IL-1 receptor antagonists, and emerging small-molecule inhibitors of the NLRP3 inflammasome (Nature Reviews Drug Discovery, 2022). These interventions are designed to dampen the excessive inflammatory signaling that drives tissue damage in IL-1-mediated diseases.

Other names

NLRP3 inflammasome pathwayIL-1 processing pathwayInflammasome-mediated IL-1β maturationPro-inflammatory cytokine production pathwayIL-1β production pathway

Drugs targeting this pathway function by neutralizing the mature IL-1β cytokine, blocking the IL-1 receptor, or inhibiting the assembly and activity of the NLRP3 inflammasome and Caspase-1 (Nature Reviews Drug Discovery, 2022).